Abstract: The instant invention relates to a method of phosphorodiamidite production that comprises: (E1) preparing a purified solution of a dialkylamine in a polar solvent as follows: —the dialkylamine dissolved in a polar solvent is contacted with a quantity of phosphorus trihalide that is sufficient to react with the alcohol impurities contained in the dialkylamine but sufficiently low to leave a major part of the dialkylamine unreacted, whereby a mixture is obtained that contains the dialkylamine in the polar solvent and reaction products of the impurities with the phosphorous trihalide; —the unreacted dialkylamine and polar solvent present in the mixture obtained in step (E1.1.

Abstract: A method of phosphorodiamidite production comprising the steps of reacting a phosphorus trihalide with a dialkyl amine in a polar solvent to form an intermediate compound. This intermediate compound is then subsequently reacted with an hydroxylalkyl compound and a dialkyl amine in the presence of a non-polar cosolvent. Following filtration to remove the solid by-product the two solvents form separate layers. This is advantageous as the upper, non-polar solvent, layer contains the high-purity phosphorodiamidite product.

Abstract: A process of producing cyanoalkyl tetraalkylphosphordiamidites at least substantially free of amine hydrohalide with improved storage stability.

Abstract: Novel styrylacrylonitrile compounds which are useful in treating a variety of cell proliferative disorders such as cancer are disclosed. The compounds are of Formula (I).

Abstract: Novel styrylacrylonitrile compounds which are useful in treating a variety of cell proliferative disorders such as cancer are disclosed.

Abstract: Novel styrylacrylonitrile compounds which are useful in treating a variety of cell proliferative disorders such as cancer are disclosed. The compounds are of Formula (1).

Abstract: A process of producing cyanoalkyl tetraalkylphosphordiamidites at least substantially free of amine hydrohalide with improved storage stability.

Abstract: An adhesive composition is provided which is suitable for the bonding of polymeric materials, in whole or in part, such as composite resins, or methacrylate-containing glass-ionomer filling materials, to tooth enamel, or tooth dentin, or to other hand tissues of the human body, such as bone. The composition comprises an unsaturated carboxylic acid ester, an unsaturated phosphate ester and other crosslinking agents. The especially preferred phosphates (which are provided as new compounds) are those of formula (I) in which: R1 is a hydrogen atom, alkyl C1-C4, or CN; R is an aliphatic, cycloaliphatic or aryl radical containing from 1 to 10 carbon atoms and having a valence of n+1; n is an integer from 1 to 5, preferably from 3 to 5.

Abstract: Novel styrylacrylonitrile compounds which are useful in treating a variety of cell proliferative disorders such as cancer are disclosed.

Abstract: A labeling reagent for use in oligonucleotide (“oligo”) synthesis, as well as a method of preparing such a labeling reagent, a method of using such a reagent for synthesizing a labeled oligonucleotide, and an oligonucleotide prepared using such a reagent. The reagent can be used to label either the 3′ or 5′ termini of a synthesized oligo, and/or for one or more positions along the oligo. The labeling reagent can be prepared by a reaction scheme that involves the initial preparation of hydroxyacids, tritylated hydroxyacids and coupling of such derivatives to diamine, wherein the amine function serves at an attachment point for labels and the hydroxyl groups can either be used to immoblize the molecules to support or can be converted to provide a phosphorylating reagent.

Abstract: Chiral, unsymmetrical bidentate organophosphorus ligands of the formula (I) are reacted with transition metal centers to form complexes with catalytic activity. The compounds contain chiral bicycloaliphatic skeletons. Synthesis of the bidentate ligands proceeds from norbornyl derivatives.

Abstract: The present invention provides an agent for preventing and curing fatty liver containing, as the effective ingredient compound, a carboxylic acid amide derivative represented by the general formula (1), (wherein R is a lower alkyl group; and X is a halogen atom), and a method for curing fatty liver by administering said agent.

Abstract: The preparation of .alpha.-carbonylphosphine oxides by oxidizing an .alpha.-hydroxyalkyl phosphine oxide with an organic hydroperoxide or of an organic peroxy acid in the presence of a compound of a Group IV to Group VIII metal in the periodic table, and novel .alpha.-hydroxybenzyl phosphine oxides. .alpha.-Carbonylphosphine oxides are used as photoinitiators for polymerizable compositions.

Abstract: A trifunctional reagent possessing a primary hydroxyl, a secondary hydroxyl, and a primary amino group. This reagent is useful in solid phase oligonucleotide synthesis for the convenient labeling of the 3'-terminus. The secondary hydroxyl may be an phosphoramidite derivative permitting the attachment to the solid phase support. The reporter molecule may be attached to the trifunctional molecule prior to the completion of the oligonucleotide synthesis or after the oligonucleotide is cleaved from the support. A preferred species of this trifunctional molecule is shown below.

Abstract: Compounds of the formula I ##STR1## in which x is 1, 2 or 3, and, if x=1, R.sup.1 is C.sub.1 -C.sub.30 alkyl, C.sub.1 -C.sub.18 alkyl substituted by halogen, --COOR.sup.2, --CN, --NR.sup.3 R.sup.4 or by --CONR.sup.3 R.sup.4, C.sub.2 -C.sub.18 alkyl which is interrupted by --NR.sup.5 --, --O-- or --S--, C.sub.3 -C.sub.18 alkenyl, C.sub.5 -C.sub.12 cycloalkyl, phenyl-C.sub.1 -C.sub.4 alkyl, phenyl which is unsubstituted or substituted by C.sub.1 -C.sub.12 alkyl, halogen, phenyl-C.sub.1 -C.sub.4 alkyl and/or C.sub.1 -C.sub.4 alkoxy, or R.sub.1 is naphthyl, a radical of the formula ##STR2## R.sub.2, R.sub.3, R.sub.4 and R.sub.5, independently of one another, are hydrogen, C.sub.1 -C.sub.18 alkyl, C.sub.5 -C.sub.12 cycloalkyl or phenyl-C.sub.1 -C.sub.4 alkyl, R.sup.6 is hydrogen, methyl, allyl or benzyl, R.sup.7 is hydrogen or --OR.sup.9, R.sup.8 is hydrogen or methyl, R.sup.9 is hydrogen or C.sub.1 -C.sub.30 alkyl, R.sup.10 and R.sup.11, independently of one another, are hydrogen or C.sub.1 -C.sub.

Abstract: Fluorescent reagents possessing an activated phosphate for the convenient covalent coupling to the 5'-hydroxyl of oligonucleotides. A class of 5'-fluorescence-tagged oligonucleptides is also disclosed.

Abstract: The use of a compound of the formula I ##STR1## in which V is an alkyl group, fluorine, chlorine, bromine, or iodine, n is an integer from 1 to 5, W is an alkyl, alkenyl, alkynyl or alkoxy group, cyanide, nitro, carboxyl, hydrogen or a cycloalkyl, aryl, aralkyl or carboalkoxy group, R.sup.1 and R.sup.2 are an alkyl, alkenyl, alkynyl, cycloalkyl or halogenoalkyl group, sodium, potassium, calcium, magnesium, aluminum, lithium, ammonium, triethylammonium or hydrogen, R.sup.1 and R.sup.2 together form a cyclic diester, R.sup.3 and R.sup.4 are an alkyl, alkenyl, alkynyl, carboalkoxy, cycloalkyl or alkoxy group, hydrogen, fluorine, chlorine, bromine or iodine and X, Y and Z are oxygen or sulfur, for the treatment of diseases caused by DNA viruses or RNA viruses is described.

Abstract: The present invention provides novel inositol phosphate analogs and a method for their use for detecting the phosphatidylinositol cycle-dependent calcium of a cell.

Abstract: Novel angiotensin II receptor antagonists of the formula ##STR1## wherein X, X.sub.1, X.sub.2, R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are as defined herein, are disclosed. These compounds are useful, for example, in the treatment of hypertension, congestive heart failure and cardiac hypertrophy.

Abstract: Disclosed is a novel naphthalocyanine compound which strongly absorbs light of near infrared region and which is chemically stable and highly soluble to an organic solvent. The naphthalocyanine compound is represented by the following formula [1]; ##STR1## wherein X represents ##STR2## (provided that R.sup.1 and R.sup.2 respectively represent a hydroxyl group, an alkyl group, an aryl group or an alkoxy group,) and M represents 2H, a metal atom, a metal oxide residue or a metal chloride residue. The present invention also provides a process for producing the naphthalocyanine compound, an intermediate thereof and a process for producing the intermediate.

Abstract: Cyclic 1-one-2-ene-3-ol compounds substituted in 2-position by an aroyl or heteroaroyl group bearing a hydrocarbylsulfonyloxy or hydrocarbylsulfonylamino substituent exhibiting herbicidal activity.

Abstract: Process for the preparation of aryloxy-benzoic acids containing a sulphonamide group by the direct reaction of a phenoxy-benzoic acid with a sulphonamide, in the presence of a halogenating agent such as P(O)Cl.sub.3.

Abstract: A carboxamide compound of the formula: ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and X are as defined and pharmaceutically acceptable salts thereof, and composition containing the compound are disclosed.The compound is useful as a calcium antagonistic agent and an antiinflammatory agent.

Abstract: A process for producing a polyfunctional cyanate ester polymer which comprises heating at least one polyfunctional cyanate ester compound having the formula:R--OCN).sub.mwherein m is an integer of at least 2 and R is one or more aromatic organic groups, and the cyanato groups are bonded to the arylene ring, in the presence of a catalytic amount of a dialkyl tin oxide having the formula:R.sup.1 R.sup.2 SnOwherein each of R.sup.1 and R.sup.2 is C.sub.1 -C.sub.30 alkyl is disclosed.

Abstract: Certain phenyl and N-heterocyclic phosphorothioates and phosphonothioates and phosphates are prepared by the reaction of an appropriate alkali metal or alkaline earth metal --0-phenyl or N-heterocyclic compound with an appropriate phosphorochloridate, phosphorochloridothioate, phosphonochloridate or phosphonochloridothioate under alkaline conditions in the presence of a tertiary amine catalyst and a nonionic surfactant having an HLB Value of from about 1 to about 20, preferably about 5 to 15, in a two-phase system, one phase being primarily the phosphorate or phosphonate reactant and a complex thereof with the tertiary amine catalyst and the other phase being an aqueous reaction medium comprising water, a buffer system, and the alkali metal or alkaline earth metal-O-phenyl or --O-N-heterocyclic compound, in the substantial or complete absence of an organic solvent the aqueous reaction medium being maintained at pH about 10 to 12 by the buffer system.

Abstract: Certain phenyl and N-heterocyclic phosphorothioates and phosphates are prepared by the reaction of an appropriate alkali metal or alkaline earth metal -O-phenyl or N-heterocyclic compound with an appropriate phosphorochloridate or phosphorochloridothioate under alkaline conditions in a liquid reaction medium and in the presence of a tertiary amine catalyst and a nonionic surfactant having a HLB Value of from about 2.5 to about 20 or more.

Abstract: The invention pertains to novel, potent anticonvulsants, analgesics, cognition enhancers and neuroprotectants achieving their action through the antagonism of specific excitatory amino acid neurotransmitter receptors. In particular, the invention is directed to .omega.-[2-(phosphonoalkylenyl)-cycloalkyl]-2-aminoalkanoic acids having general formula: ##STR1## wherein R.sub.1 and R.sub.2 are the same or different and are selected from the group consisting of hydrogen, lower alkyl (C.sub.1 to C.sub.6), alkyl (C.sub.7 to C.sub.12), fatty acid chain (C.sub.13 to C.sub.24), aryl, aralkyl, hydroxyl; the stereoisomers being in their resolved or racemic form; n and m=0,1,2 or 3; z=0,1 or 2; the cycloalkyl ring being replaced with the cycloalkenyl ring; and the pharmaceutically acceptable salts and derivatives thereof.

Abstract: The invention pertains to novel, potent anticonvulsants, analgesics and cognition enhancers achieving their action through the antagonism of specific excitatory amino acid neurotransmitter receptors. In particular, the invention is directed to .omega.-[2-phosphonoalkyleneyl)phenyl]-2-aminoalkanoic acids having general formula: ##STR1## Wherein R.sub.1 and R.sub.2 are the same or different and are selected from the group consisting of hydrogen, lower alkyl, halogen, --CH.dbd.CH--CH.dbd.CH.dbd., amino, nitro, trifluoromethyl or cyano; n and m=0, 1, 2, or 3; and the pharmaceutically acceptable salts and derivatives thereof.

Abstract: Dihalovinylphenyl phosphates of the formula I ##STR1## where A and B are each halogen or trihaloalkyl, X is oxygen or sulfur, Y and Z are each oxygen, sulfur or --NH--, R.sup.1 is alkyl, R.sup.2 is alkyl, haloalkyl, alkoxyalkyl or alkylthioalkyl, and R.sup.3, R.sup.4 and R.sup.5 independently of one another are each hydrogen, halogen, nitro, alkyl, cyano, alkoxy, alkoxyalkoxy, alkylthioalkylthio, alkoxyalkyl, alkylthioalkyl, alkylthio, trihaloalkyl or trihaloalkoxy, and pesticides containing these compounds.